CD22 and myasthenia gravis: In this study, plasma proteomic analysis revealed that the plasma levels of soluble CD22 decreased between refractory seronegative MG and HC or AChR-positive MG and correlated significantly with disease severity, immune cell frequency, and mRNA expression levels.